Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,500 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 August 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 207 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 117 results:
Author [ Title(Asc)] Type Year
Filters: Author is van Staa, T. P.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
V
R. Boggon, Hubbard, R., Smeeth, L., Gulliford, M., Cassell, J., Eaton, S., Pirmohamed, M., and van Staa, T. P., “Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study”, BMC Pulm Med, vol. 13, p. 32, 2013.
U
A. M. Gallagher, Leighton-Scott, J., and van Staa, T. P., “Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study”, Clin Ther, vol. 31, pp. 1707-15, 2009.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
T. P. van Staa, Wegman, S., de Vries, F., Leufkens, B., and Cooper, C., “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
P. C. Souverein, Berard, A., van Staa, T. P., Cooper, C., Egberts, A. C., Leufkens, H. G., and Walker, B. R., “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
T. P. van Staa, Abenhaim, L., and Cooper, C., “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
F. de Vries, Souverein, P. C., Cooper, C., Leufkens, H. G., and van Staa, T. P., “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
P. C. Souverein, Webb, D. J., Weil, J. G., van Staa, T. P., and Egberts, A. C., “Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy”, Neurology, vol. 66, pp. 1318-24, 2006.
P. C. Souverein, van Staa, T. P., Egberts, A. C., De la Rosette, J. J., Cooper, C., and Leufkens, H. G., “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
T
R. Y. van der Velde, Wyers, C. E., Teesselink, E., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., Harvey, N. C., and van Staa, T. P., “Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity”, Bone, vol. 94, pp. 50-55, 2017.
S
R. M. Joseph, Soames, J., Wright, M., Sultana, K., van Staa, T. P., and Dixon, W. G., “Supplementing electronic health records through sample collection and patient diaries: A study set within a primary care research database”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 239-242, 2018.
T. P. van Staa and Sprafka, J. M., “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
R. Boggon, Timmis, A., Hemingway, H., Raju, S., Malvestiti, F. M., and van Staa, T. P., “Smoking cessation interventions following acute coronary syndrome: a missed opportunity?”, Eur J Prev Cardiol, vol. 21, pp. 767-73, 2014.
J. V. Been, Szatkowski, L., van Staa, T. P., Leufkens, H. G., van Schayck, O. C., Sheikh, A., de Vries, F., and Souverein, P., “Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations”, Sci Rep, vol. 5, p. 15246, 2015.
T. P. van Staa, Geusens, P., Pols, H. A., de Laet, C., Leufkens, H. G., and Cooper, C., “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
M. T. Bazelier, van Staa, T. P., Uitdehaag, B. M., Cooper, C., Leufkens, H. G., Vestergaard, P., Bentzen, J., and de Vries, F., “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
F. de Vries, van Staa, T. P., Bracke, M. S., Cooper, C., Leufkens, H. G., and Lammers, J. W., “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
R. Y. van der Velde, Wyers, C. E., Curtis, E. M., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., van Staa, T. P., and Harvey, N. C., “Secular trends in fracture incidence in the UK between 1990 and 2012”, Osteoporos Int, vol. 27, pp. 3197-3206, 2016.
V. 3rd. Lo Re, Haynes, K., Ming, E. E., J. Ives, W., Horne, L. N., Fortier, K., Carbonari, D. M., Hennessy, S., Cardillo, S., Reese, P. P., Reddy, K. R., Margolis, D., Apter, A., Kimmel, S. E., Roy, J., Freeman, C. P., Razzaghi, H., Holick, C. N., Esposito, D. B., van Staa, T. P., Bhullar, H., and Strom, B. L., “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.
J. T. Nielen, Dagnelie, P. C., Emans, P. J., Veldhorst-Janssen, N., Lalmohamed, A., van Staa, T. P., Boonen, A. E., van den Bemt, B. J., and de Vries, F., “Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1245-1252, 2016.
R
A. M. Gallagher, Setakis, E., Plumb, J. M., Clemens, A., and van Staa, T. P., “Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients”, Thromb Haemost, vol. 106, pp. 968-77, 2011.
S. Bours, de Vries, F., van den Bergh, J. P. W., Lalmohamed, A., van Staa, T. P., Leufkens, H. G. M., Geusens, P. P. P., Drent, M., and Harvey, N. C., “Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort”, Osteoporos Int, vol. 27, pp. 1603-1610, 2016.
E. Martin-Merino, Petersen, I., Hawley, S., Alvarez-Gutierrez, A., Khalid, S., Llorente-Garcia, A., Delmestri, A., Javaid, M. K., van Staa, T. P., Judge, A., Cooper, C., and Prieto-Alhambra, D., “Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK”, Osteoporos Int, vol. 29, pp. 467-478, 2018.
I. J. A. de Bruin, Wyers, C. E., Souverein, P. C., van Staa, T. P., Geusens, P., van den Bergh, J. P. W., de Vries, F., and Driessen, J. H. M., “The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK”, Osteoporos Int, 2020.
M. E. Jones, Campbell, G., Patel, D., Brunner, E., Shatapathy, C. C., Murray-Thomas, T., van Staa, T. P., and Motsko, S., “Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database”, Cardiovasc Psychiatry Neurol, vol. 2013, p. 647476, 2013.
D. Gibson-Smith, Klop, C., Elders, P. J., Welsing, P. M., van Schoor, N., Leufkens, H. G., Harvey, N. C., van Staa, T. P., and de Vries, F., “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
G. W. Hugenholtz, Heerdink, E. R., van Staa, T. P., Nolen, W. A., and Egberts, A. C., “Risk of hip/femur fractures in patients using antipsychotics”, Bone, vol. 37, pp. 864-70, 2005.
M. T. Bazelier, de Vries, F., Vestergaard, P., Herings, R. M., Gallagher, A. M., Leufkens, H. G., and van Staa, T. P., “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
A. Lalmohamed, de Vries, F., Bazelier, M. T., Cooper, A., van Staa, T. P., Cooper, C., and Harvey, N. C., “Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study”, Bmj, vol. 345, p. e5085, 2012.
A. M. Gallagher, Smeeth, L., Seabroke, S., Leufkens, H. G., and van Staa, T. P., “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
D. C. Braeken, Rohde, G. G., Franssen, F. M., Driessen, J. H., van Staa, T. P., Souverein, P. C., Wouters, E. F., and de Vries, F., “Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom”, Int J Chron Obstruct Pulmon Dis, vol. 12, pp. 2425-2432, 2017.
K. B. Handoko, Souverein, P. C., van Staa, T. P., Meyboom, R. H., Leufkens, H. G., Egberts, T. C., and van den Bemt, P. M., “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
R. Boggon, Lip, G. Y., Gallagher, A. M., and van Staa, T. P., “Resource utilization and outcomes in patients with atrial fibrillation: a case control study”, Appl Health Econ Health Policy, vol. 10, pp. 249-59, 2012.
Y. Li, Molter, A., White, A., Welfare, W., Palin, V., Belmonte, M., Ashcroft, D. M., Sperrin, M., and van Staa, T. P., “Relationship between prescribing of antibiotics and other medicines in primary care: a cross-sectional study”, Br J Gen Pract, vol. 69, pp. e42-e51, 2019.
F. de Vries, de Vries, C., Cooper, C., Leufkens, B., and van Staa, T. P., “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
Q
K. Wing, Bhaskaran, K., Pealing, L., Root, A., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., and Douglas, I., “Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study”, J Antimicrob Chemother, vol. 72, pp. 2636-2646, 2017.
A. M. Gallagher, de Vries, F., Plumb, J. M., Hass, B., Clemens, A., and van Staa, T. P., “Quality of INR control and outcomes following venous thromboembolism”, Clin Appl Thromb Hemost, vol. 18, pp. 370-8, 2012.
P
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
T. P. van Staa, Carr, D. F., O'Meara, H., McCann, G., and Pirmohamed, M., “Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment”, Br J Clin Pharmacol, vol. 78, pp. 649-59, 2014.
T. P. van Staa, Gulliford, M., Ng, E. S., Goldacre, B., and Smeeth, L., “Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?”, PLoS One, vol. 9, p. e106455, 2014.
S. Rietbrock, Olson, M., and van Staa, T. P., “The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates”, Qjm, vol. 102, pp. 35-42, 2009.
T. P. van Staa, Leufkens, H., Abenhaim, L., and Cooper, C., “Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
[Page last reviewed 5 August 2020]